Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy.

Lavoué V, Cabillic F, Toutirais O, Thedrez A, Dessarthe B, de La Pintière CT, Daniel P, Foucher F, Bauville E, Henno S, Burtin F, Bansard JY, Levêque J, Catros V, Bouet-Toussaint F.

Int J Cancer. 2012 Aug 15;131(4):E449-62. doi: 10.1002/ijc.27353. Epub 2011 Dec 21.

2.

Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.

Cabillic F, Toutirais O, Lavoué V, de La Pintière CT, Daniel P, Rioux-Leclerc N, Turlin B, Mönkkönen H, Mönkkönen J, Boudjema K, Catros V, Bouet-Toussaint F.

Cancer Immunol Immunother. 2010 Nov;59(11):1611-9. doi: 10.1007/s00262-010-0887-0. Epub 2010 Jun 26.

PMID:
20582413
3.

A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients.

Thedrez A, Lavoué V, Dessarthe B, Daniel P, Henno S, Jaffre I, Levêque J, Catros V, Cabillic F.

PLoS One. 2013 May 23;8(5):e63322. doi: 10.1371/journal.pone.0063322. Print 2013.

4.

Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer.

Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K.

Cancer Med. 2014 Apr;3(2):362-75. doi: 10.1002/cam4.196. Epub 2014 Feb 7.

5.

Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.

Izumi T, Kondo M, Takahashi T, Fujieda N, Kondo A, Tamura N, Murakawa T, Nakajima J, Matsushita H, Kakimi K.

Cytotherapy. 2013 Apr;15(4):481-91. doi: 10.1016/j.jcyt.2012.12.004. Epub 2013 Feb 5.

PMID:
23391461
6.
7.

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F, Hayday AC.

Clin Exp Immunol. 2010 Aug;161(2):290-7. doi: 10.1111/j.1365-2249.2010.04167.x. Epub 2010 May 10.

8.

Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.

Mattarollo SR, Kenna T, Nieda M, Nicol AJ.

Cancer Immunol Immunother. 2007 Aug;56(8):1285-97. Epub 2007 Jan 31.

PMID:
17265022
9.

Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.

Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas de la Pintière C, Daniel P, Genetet N, Meunier B, Dupont-Bierre E, Boudjema K, Catros V.

Cancer Immunol Immunother. 2008 Apr;57(4):531-9. Epub 2007 Sep 1.

PMID:
17764010
10.

Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.

Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, Sato K, Hosoi A, Nakajima J, Yoshida Y, Shiraishi K, Nakagawa K, Kakimi K.

Cytotherapy. 2008;10(8):842-56. doi: 10.1080/14653240802419328.

PMID:
19016372
11.

Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate.

Li Z, Peng H, Xu Q, Ye Z.

J Orthop Res. 2012 May;30(5):824-30. doi: 10.1002/jor.21579. Epub 2011 Oct 24.

12.

V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.

D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, Guggino G, Meraviglia S, Caccamo N, Messina A, Salerno A, Di Raimondo F, Vigneri P, Stassi G, Fourniè JJ, Dieli F.

J Immunol. 2010 Mar 15;184(6):3260-8. doi: 10.4049/jimmunol.0903454. Epub 2010 Feb 12.

13.

Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.

Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K.

J Immunother. 2011 Mar;34(2):202-11. doi: 10.1097/CJI.0b013e318207ecfb.

PMID:
21304399
14.

IL-23R and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells expressing high levels of cytotoxic mediators and producing IFN-gamma and IL-17.

Moens E, Brouwer M, Dimova T, Goldman M, Willems F, Vermijlen D.

J Leukoc Biol. 2011 May;89(5):743-52. doi: 10.1189/jlb.0910501. Epub 2011 Feb 17.

15.

Expansion of human peripheral blood γδ T cells using zoledronate.

Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, Kakimi K.

J Vis Exp. 2011 Sep 9;(55). pii: 3182. doi: 10.3791/3182.

16.

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.

Khan AN, Kolomeyevskaya N, Singel KL, Grimm MJ, Moysich KB, Daudi S, Grzankowski KS, Lele S, Ylagan L, Webster GA, Abrams SI, Odunsi K, Segal BH.

Oncotarget. 2015 May 10;6(13):11310-26.

17.
18.

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.

Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M.

Br J Cancer. 2011 Sep 6;105(6):778-86. doi: 10.1038/bjc.2011.293. Epub 2011 Aug 16.

19.
20.

Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.

Yang W, Feng J, Chang X, Fu T, Ye X, Zhang H, Li X, Wen H, Feng L, Tong C, Cui H.

Gynecol Oncol. 2007 Apr;105(1):238-43.

PMID:
17383546
Items per page

Supplemental Content

Write to the Help Desk